Advances in neovascular macular degeneration, presented at ASRS 2025, include efficacy of aflibercept 8 mg as well as ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

New peptide drugs could take aim at a broader range of proteins that cause certain cancers, viral infections, and brain ...

The brain’s map of the body remains largely unaffected by amputation, potentially informing phantom limb pain management and ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

A phase 3 trial suggests reducing the use of cisplatin when treating nasopharyngeal carcinoma with toripalimab-based ...

In nine studies (76 patients), the anti-IgE monoclonal antibody omalizumab (Xolair), given every 2-4 weeks at doses ranging ...

The American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines on deferred umbilical cord clamping ...

The FDA has approved brensocatib tablets in 10-mg and 25-mg doses as once-daily treatment for non-cystic fibrosis ...

A deep-learning analysis of three-dimensional optical coherence tomography scans shows promising accuracy in distinguishing ...

An extensive analysis shows scant evidence that ketamine or other NMDA receptor agonists reduce chronic noncancer pain but ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...